SCHEMBL168530

SCHEMBL168530

C=CC(=O)Nc1cc[c]cc1

nearest known ligand 0.64

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 15/20 0.64
F13A1 P00488 5/20 0.60
TGM1 P22735 5/20 0.60
LMNA P02545 1/20 0.60
TGM3 Q08188 1/20 0.60
THRA P10827 1/20 0.46
THRB P10828 1/20 0.46
GSTO1 P78417 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL439369 0.84 TGM2 (0.79) TGM2F13A1TGM1LMNATGM3
SCHEMBL8315998 0.79 TGM2 (0.39) TGM2F13A1TGM1LMNATGM3
SCHEMBL81209 0.78 TGM2 (1.00) TGM2F13A1TGM1LMNATGM3
SCHEMBL995472 0.77 TGM2 (0.61) TGM2F13A1TGM1LMNATGM3
SCHEMBL133445 0.77 TGM2 (0.68) TGM2F13A1TGM1LMNATGM3
SCHEMBL28240522 0.77 TGM2 (0.96) TGM2F13A1TGM1LMNATGM3
SCHEMBL7270679 0.77 TGM2 (0.68) TGM2F13A1TGM1LMNATGM3
SCHEMBL30211836 0.77 TGM2 (0.96) TGM2F13A1TGM1LMNATGM3
SCHEMBL28703875 0.77 TGM2 (0.68) TGM2F13A1TGM1LMNATGM3
SCHEMBL25365033 0.76 MTNR1A (0.47) TGM2F13A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113082220-B pH-responsive surface charge reversal nano-carrier and preparation method and application thereof 西北工业大学 2022-08-23 CN claimed
WO-2022012550-A1 SUBSTITUTED 1H-IMIDAZO [1, 2-B] PYRAZOLE-3-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS HENAN NORMAL UNIVERSITY (CN) 2022-01-20 WO claimed
EP-3847220-A1 UV-CURABLE HOT MELT ADHESIVE COMPOSITIONS FOR FLOORING APPLICATIONS BASF SE (DE) 2021-07-14 EP claimed
CN-113082220-A pH-responsive surface charge reversal nano-carrier and preparation method and application thereof 西北工业大学 2021-07-09 CN claimed
WO-2021110142-A1 SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS HENAN NORMAL UNIVERSITY (CN) 2021-06-10 WO claimed
CN-112585230-A UV curable hot melt adhesive composition for floor application 巴斯夫欧洲公司 2021-03-30 CN claimed
EP-2915186-B1 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT VERSUM MAT US LLC (US) 2020-10-28 EP claimed
CN-110483691-A A kind of terpolymer crosslinking agent and its application in the dedicated cationic membrane preparation of diffusion dialysis UNIV ANHUI 2019-11-22 CN claimed
CN-110403915-A DNA and the hybridized nucleic acids pharmaceutical carrier of polymer and its preparation method and application UNIV TIANJIN 2019-11-05 CN claimed
CN-110194877-A A kind of Nanometer composite hydrogel and its preparation method and application 湘潭大学 2019-09-03 CN claimed
CN-106699940-A Preparing method of composite nanoparticle based on polypropylene amide benzene boric acid 华北科技学院 2017-05-24 CN claimed
CN-103977776-B The quick intelligent aqueous gel capable of a kind of sugar based on gold surface and synthetic method thereof SUZHOU QUANTZ MEDICAL TECHNOLOGY CO., LTD. (CN) 2016-04-13 CN claimed
CN-104148038-B A kind of based on gold surface boric acid class glucose-sensitive type trace hydrogel and preparation method thereof SUZHOU QUANTZ MEDICAL TECHNOLOGY CO., LTD. (CN) 2016-02-10 CN claimed
CN-104148038-A Boric acid glucose-sensitive imprinted hydrogel based on gold surface and preparation method of hydrogel SUZHOU KANGCI MEDICAL TECHNOLOGY CO LTD 2014-11-19 CN claimed
CN-103977776-A Sugar-sensitive intelligent hydrogel based on gold surface and synthesis method thereof SUZHOU QUANTZ MEDICAL TECHNOLOGY CO LTD 2014-08-13 CN claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
CN-101616920-A The 1-H-pyrazolo (3,4b) pyrimidine derivatives and as the purposes of mitotic kinase conditioning agent BIOGEN IDEC INC 2009-12-30 CN claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 TGM2 3581/4885F13A1 4237/4885TGM1 1397/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 TGM2 3581/4885F13A1 4237/4885TGM1 1397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.